Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis

Journal of Viral Hepatitis

Volumn 24, Issue 11, 2017, Pages 936-943

  Wedemeyer, H ^a   Craxi A ^b   Zuckerman, E ^c   Dieterich, D ^d   Flisiak, R ^e   Roberts, S K ^f   Pangerl, A ^g   Zhang, Z ^g   Martinez, M ^g   Bao, Y ^g   Calleja, J L ^h  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF PALERMO   (Italy)

^c CARMEL MEDICAL CENTER   (Israel)

^d MOUNT SINAI HOSPITAL   (United States)

^e Klinika Chorob Zakaznych I N   (Poland)

^f MONASH UNIVERSITY   (Australia)

^g ABBVIE INC   (United States)

^h HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

2D; 3D; HCV genotypes 1 and 4; hepatitis C; meta analysis; real world effectiveness

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR PLUS OMBITASVIR PLUS PARITAPREVIR PLUS RIBAVIRIN PLUS RITONAVIR; UNCLASSIFIED DRUG; ABT-267; ABT-450; ANILIDE; CARBAMIC ACID DERIVATIVE; MACROCYCLIC COMPOUND; RIBAVIRIN; RITONAVIR;

ARTICLE; CHILD PUGH SCORE; COHORT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; KIDNEY DISEASE; LIVER CIRRHOSIS; META ANALYSIS; PRIORITY JOURNAL; RECURRENCE RISK; SUSTAINED VIROLOGIC RESPONSE; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; COMORBIDITY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ANILIDES; ANTIVIRAL AGENTS; CARBAMATES; COMORBIDITY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MACROCYCLIC COMPOUNDS; RIBAVIRIN; RITONAVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 85021744504     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12722     Document Type: Article

References (50)

1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87.
2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57.
3. Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124-1135.
4. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529-538.
5. Bezemer G, Van Gool AR, Verheij-Hart E, et al. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol. 2012;12:11.
6. Maasoumy B, Wedemeyer H. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol. 2012;26:401-412.
7. van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65(1 Suppl):S95-S108.
8. Pawlotsky JM, Feld JJ, Zeuzem S, Hoofnagle JH. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62(1 Suppl):S87-S99.
9. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-1992.
10. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973-1982.
11. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223-1231.
12. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-1614.
13. Jacobson IM, Dufour JF, Wedemeyer H, et al. 99.7% sustained virologic response rate in 369 HCV genotype 1b-infected patients treated with label-recommended regimen of ombitasvir/paritaprevir/r and dasabuvir with or without ribavirin. Am J Gastroenterol. 2015;110(S1):S850-S851.
14. Rustgi V, Wedemeyer H, Pockros P, et al. Sustained virologic response rate of 96% in HCV genotype 1a-infected patients treated with ombitasvir/paritaprevir/r and dasabuvir with ribavirin. Am J Gastroenterol. 2015;110(S1):S862.
15. Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. J Hepatol. 2016;64:301-307.
16. Asselah T, Hézode C, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1:25-35.
17. Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502-2509.
18. Waked I, Shiha G, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1:36-44.
19. Bansal S, Singal AK, McGuire BM, Anand BS. Impact of all oral anti-hepatitis C virus therapy: a meta-analysis. World J Hepatol. 2015;7:806-813.
20. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.
21. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015;64:1824-1833.
22. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889-1898.
23. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.
24. Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016;22(6 Spec No.):SP205-SP211.
25. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Real world effectiveness of ledipasvir/sofosbuvir in 4365 treatment-naive genotype 1 hepatitis c infected patients. Hepatology. 2016;64:405-414.
26. Mauss S, Schewe K, Rockstroh JK, et al. Sofosbuvir-based treatments for patients with hepatitis C virus (HCV) mono-infection and human immunodeficiency virus (HIV)-HCV co-infection with genotype 1and 4 in clinical practice – Results from the GErmanhepatitis C COhort(GECCO). The Liver Meeting (AASLD). 2016.
27. Tacke F, Gunther R, Buggisch P, et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 2017;37:205-211.
28. Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol. 2016;2:34-37.
29. Freeman M, Tukey J. Transformations related to the angular and the square root. Ann Math Stat. 1950;21:607-611.
30. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974-978.
31. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539-1558.
32. VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) [package insert]. AbbVie, North Chicago, IL.
33. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594-1603.
34. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604-1614.
35. Poordad F, Agarwal K, Younes Z, et al. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis. 2015;60:608-610.
36. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447-462.
37. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-2607.
38. Kohli A, Kapoor R, Sims Z, et al. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis. 2015;15:1049-1054.
39. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1-13.
40. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344-355.
41. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231.
42. Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol. 2016;64:763-765.
43. Poordad F, Nelson DR, Feld JJ, et al., editors. Pooled Safety Assessment of Ombitasvir/Paritaprevir/Ritonavir +/− Dasabuvir +/− Ribavirin in HCV-Infected Patients with Child-Pugh A Compensated Cirrhosis. EASL OPTIMIZE; 2016 12 April 2016; Barcelona, Spain.
44. SOVALDI (sofosbuvir) [package insert]. Gilead Sciences. Foster City, CA; 2014.
45. EPCLUSA (sofosbuvir and velpatasvir) [package insert]. Gilead Sciences. Foster City, CA; 2016.
46. HARVONI (ledipasvir and sofosbuvir) tablets [package insert]. Gilead Sciences. ed. Foster City, CA; February 2016.
47. Pockros PJ, Reddy KR, Mantry PS, et al. Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology. 2016;150:1590-1598.
48. Clase CM, Kiberd BA, Garg AX. Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pract. 2007;105:c178-c184.
49. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943.
50. Hinrichsen H, Wedemeyer H, Christensen S, et al. Real-world safety and effectiveness of ombitasvir/paritaprevir/r with dasabuvir and/or ribavirin in the German hepatitis C registry. The International Liver Congress (EASL); 2016.